Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma

Cancer Science

Volumn 102, Issue 9, 2011, Pages 1622-1629

  Suzuki, Shiro ^a,b   Yoshikawa, Toshiaki ^a   Hirosawa, Tomoya ^b,c   Shibata, Kiyosumi ^b   Kikkawa, Fumitaka ^b   Akatsuka, Yoshiki ^c,d   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GAMMA INTERFERON; GLYPICAN 3; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; PACLITAXEL; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL SURFACE; CLEAR CELL CARCINOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADENOCARCINOMA, CLEAR CELL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; EPITOPES; FEMALE; GLYPICANS; HLA-A2 ANTIGEN; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL; VACCINES, SUBUNIT;

EID: 80051824942     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02003.x     Document Type: Article

References (33)

1. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
2. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-9.
3. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78: 2157-63.
4. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108: 497-501.
5. Nakatsura T, Yoshitake Y, Senju S et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 16-25.
6. Nakatsura T, Kageshita T, Ito S et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 6612-21.
7. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000; 89: 418-22.
8. Toretsky JA, Zitomersky NL, Eskenazi AE et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001; 23: 496-9.
9. Maeda D, Ota S, Takazawa Y et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009; 22: 824-32.
10. Aviel-Ronen S, Lau SK, Pintilie M et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008; 21: 817-25.
11. Komori H, Nakatsura T, Senju S et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-97.
12. Yoshikawa T, Nakatsugawa M, Suzuki S et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102: 918-25.
13. Akatsuka Y, Goldberg TA, Kondo E et al. Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 2002; 59: 502-11.
14. Sakurai M, Shibata K, Umezu T et al. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells. Gynecol Oncol 2010; 119: 332-6.
15. Shirakawa H, Suzuki H, Shimomura M et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 1403-7.
16. Shirakawa H, Kuronuma T, Nishimura Y et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34: 649-56.
17. Ikuta Y, Nakatsura T, Kageshita T et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005; 11: 8079-88.
18. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 2005; 19: 71-7.
19. Hayashi E, Motomura Y, Shirakawa H et al. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol Rep 2009; 22: 149-54.
20. Motomura Y, Ikuta Y, Kuronuma T et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32: 985-90.
21. Motomura Y, Senju S, Nakatsura T et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006; 66: 2414-22.
22. Nakatsura T, Komori H, Kubo T et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10: 8630-40.
23. Gribben JG, Ryan DP, Boyajian R et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005; 11: 4430-6.
24. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 878-87.
25. Arlen PM, Gulley JL, Parker C et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-9.
26. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007; 13: 3776-82.
27. Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68: 5955-64.
28. Vicari AP, Luu R, Zhang N et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58: 615-28.
29. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
30. Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-24.
31. Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL. J Immunol 2000; 164: 4941-54.
32. Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. J Immunol 2001; 166: 3564-73.
33. Srivastava RK, Sasaki CY, Hardwick JM, Longo DL. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med 1999; 190: 253-65.